The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 24, 2019

Filed:

Sep. 06, 2016
Applicant:

The Research Foundation for the State University of New York, Albany, NY (US);

Inventors:

Douglas S. Conklin, Niskayuna, NY (US);

Xianhui Wang, Albany, NY (US);

Leila Kokabee, Albany, NY (US);

Assignee:

University Of New York, Albany, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/519 (2006.01); C07K 16/40 (2006.01); A61K 31/713 (2006.01); C12N 15/113 (2010.01); A61K 31/704 (2006.01); A61K 45/06 (2006.01); C12N 9/12 (2006.01); G01N 33/573 (2006.01); G01N 33/574 (2006.01); C07K 14/705 (2006.01);
U.S. Cl.
CPC ...
C07K 16/40 (2013.01); A61K 31/519 (2013.01); A61K 31/704 (2013.01); A61K 31/713 (2013.01); A61K 45/06 (2013.01); C07K 14/705 (2013.01); C12N 9/1205 (2013.01); C12N 15/1137 (2013.01); C12Y 207/10001 (2013.01); C12Y 207/10002 (2013.01); G01N 33/573 (2013.01); G01N 33/57415 (2013.01); C12N 2310/14 (2013.01); G01N 2333/9121 (2013.01);
Abstract

Receptor protein kinases (RPTKs) transmit extracellular signals across the plasma membrane to cytosolic proteins, stimulating formation of complexes that regulate key cellular functions. Over half of the known tyrosine kinases are implicated in human cancers and are therefore highly promising drug targets. A large-scale loss-of-function analysis of tyrosine kinases using RNA interference in the clinically relevant Erb-B2 positive, BT474 breast cancer cell line showed that Bruton's tyrosine kinase (BTK), a cytosolic, non-receptor tyrosine kinase that has been extensively studied for its role in B cell development, is required, in altered form, for BT474 breast cancer survival. This alternative form contains an amino-terminal extension that is also present in tumorigenic breast cells at significantly higher levels than in normal breast cells. Thus, embodiments of the invention find application in the field of cancer therapy.


Find Patent Forward Citations

Loading…